Evaluation of Inflammatory Markers in Graves’ Disease Patients in Orlu, Imo State
Keywords:
inflammatory markers, graves’ disease, orluAbstract
The study evaluated the Molecular Inflammatory and Immunological markers in Graves’ Disease patients in Orlu, Imo State. This work included eighty (80) Graves’ Disease patients within the age bracket of 30-60 years old of both gender (males and females), grouped into two (group 1; those without Graves’ orbitopathy, GO) and (group 2; those with Graves’ orbitopathy). The two groups were of equal sample size of forty (40) study subjects each matched with Age and Gender controls. CRP, IL-23, IFN-gamma, and TNF-alpha, were all measured with different tests kits of Elisa method. However, ESR was measured with Westergren methods. The SPSS statistical computer software (version 21) was used for the analysis. The study showed that ESR,CRP,IL-23, IFN- gamma, TFN- alpha mean serum levels were significantly higher in the two groups when compared to their respective controls ESR mm/hr (32.15 ± 7.08; control as 12.05 ± 4.24), CRP mg/L ( 20.55± 8.98; control as 5.40 ± 2.57) IL-23pg/ml ( 37.45 ± 13.63; control as 10.85± 5.10), IFN-gamma pg/ml (9.46± 5.28; control as 2.85 ± 1.00), TFN-alpha (22.80 ± 4.49; control as 9.10± 3.00) for males and ( 33.23± 8.57±; control as 13.24±. 4.64), (21.34± 8.24; control as 6.20± 2.77), (38.02± 13.75; control as 11.48± 5.82), (10.05± 5.97; control as 3.14± 1.08), (23.56± 4.85; control as 9.85± 3.14) for females. Again, there was a significantly lower mean serum levels of those inflammatory markers in grp 1 than in grp 2; ESR ( 25.70 ± 3.37; control as 38.60 ± 5.66) , CRP( 14.20 ± 4.27 ; control as 26.90 ± 7.91), IL-23 (26.00 ± 2.51;control as 48.90± 9.96) ,IFN-gamma ( 5.35 ± 0.66 ;control as 13.57 ± 4.62), TFN -alpha (25.70 ± 3.46 ;control as 19.90 ± 3.41) for males and (26.45± 3.37; control as 13.02± 5.65), (14.92± 5.01; control as 4.90± 2.21), ( 26.75± 2.21; control as 10.03± 5.28), (6.15± 0.75; control as 2.95± 0.98), (26.20± 3.57; control as 9.80± 3.48) for females.
References
1. Chen, Y. (2023). The global epidemiology of Graves’ Disease: A Systematic review. Journal of Autoimmune Diseases, 6(1),100-112.
2. Diana, T., Olivo, P., D. and Kahaly, G., J. (2018). Thyrotropin Receptor Blocking Antibodies. Hormone of Metabolic Resources, 50(12):853-862.
3. Adeleye, J. O., Emuze, M. E., Azeez, T., A., Esan, A., Baalogun, W., O. and Akande, T., O. (2020). Clinical Profiles of males with Graves’ disease: A two-year review in a tertiary hospital in Nigeria. Thyroid Disorders and Therapy, 9, 240.
4. Zhang, P., Mo, D., Lin, F. and Dai, H. (2025). Relationship between novel inflammatory markers derived from high-sensitivity C-reactive protein and heart failure: a cross-sectional study. British Medical Council Cardiovascular Disorders, 25(1):111.
5. Antonelli, A., Ferrari, S., M., Ragusa, F., Elia, G., Paparo, S., R., Ruffilli, I., Patrizio, A., Giusti, C., Gonnella, D., Cristauda, A., Foddis, R. and Shoenfeld, Y. (2020). Graves' disease: Epidemiology, genetic and environmental risk factors and viruses. Best Practice and Research. Clinical Endocrinology and Metabolism, 34(1), 101387.
6. Bartalena, L. (2022). Current Concepts regarding Graves Orbitopathy. Journal of Internal Medicine,292 (5), 692-716.
7. Cunha, F., S. and Erensztein, E., B. (2020). Novel clinical manifestations in pediatric thyroid disorders. Journal of clinical Research in pediatric Endocrinology, 12(1),1-11.
8. Darooghegi, M., Milajerdi, A, Koohdani, F., Surkan, P., J. and Azadbakht, L. (2019). Garlic Supplementation Reduces Circulating C-reactive Protein, Tumor Necrosis Factor, and Interleukin-6 in Adults: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Journal of Nutrition, 149(4):605-618.
9. Dittrich, R., Kaposi, A., J., Gonzalez, I., J. and Rodwell, T., C. (2016). C-Reactive Protein as a diagnostic marker in various diseases. Journal of clinical and Diagnostic Research, 10(9)1-5.
10. Burke, M. and Armitage, M. (2024). Erythrocyte Sedimentation Rate Vs C- reactive protein: Understanding the differences. GoodRx, 137 (7) 2056.
11. Kustrimovic, N., Gallo, D., Piantamida, E., Bartalena, L., Lui, A., Zerbinati, N., Tanda, M. L. and Mortara, L. (2023). Regulatory T-Cells in the pathogenesis of Graves Disease. International Journal of Molecular Sciences, 24(22), 16432.
12. Ehlers, M, Schott, M. and Allelein, S. (2019). Graves' disease in clinical perspective. Frontier in Bioscience, 24(1):35-47.
13. Gritxi, S., I., Gazzinelli-Guimaraes, P.H. and Dayan, C. (2023). The role of environmental factors in the development of graves diseases. A narrative review. Journal of clinical and Translational Research, 9(3),1-16.
14. Smith, T. J. and Hegedüs, L. (2018). Graves' disease. New England Journal of Medicine, 378(19), 1827-1836.
15. Dick, A., G., Magill, N., White, T., C., H., Kokkinakis, M. and Norman-Taylor, F. (2019). C-reactive protein: what to expect after bony hip surgery for non ambulatory children and adolescents with cerebral palsy. Journal of Pediatric Orthopaedics, 28(4):309-313.
16. 16.Lee, C.C. (2019). Diagnostic value of C-Reactive Protein in infectious diseases. Journal of infection and public health, 12(3),347-353.
17. Han, Y., Zhang, C., Wang, Y., Li, S., Xu, L., Gao, L., and Gao, Y. (2022). “Inflammatory Status Persists During the Euthyroid Phase in Graves’ Disease.” Frontiers in Endocrinology, 13: 909998.
18. Desai, M. P., and Brinton, D. R. (2019). Understanding the Etiology and Management of Graves' Disease: A Review. Journal of the Endocrine Society, 3(9), 1697-1707.
19. Mouliou, D. S. (2023). C-Reactive Protein: Pathophysiology, Diagnosis, False test results and a novel Diagnostic Algorithm for Clinicians. Diseases,11(4), 132.
20. Pope, J. E. and Choy, E.H. (2021). "C-reactive protein and implications in rheumatoid arthritis and associated comorbidities". Seminars in Arthritis and Rheumatism, 51 (1): 219–229.
21. Rraklli, E., Gjika, F. and Cibuku, O. (2025). The role of Erythrocyte Sedimentation Rate as a prognostic factor in intracerebral haemorrhage. Journal of Neurology Research, 15 (1), 33-38.
22. Sheriff, A., Kayser, S., Brunner, P. and Vogt, B. (2021). "C-Reactive Protein Triggers Cell Death in Ischemic Cells". Frontiers in Immunology,12: 630 -730.
23. Leucuta, D. C., Fumeaux, P. A., Almasan, O., Popa, S. L. and Ismaiel, A. (2025). Inflammatory Markers as predictors of Diabetic Nephropathy in type 2 Diabetes Mellitus: A systematic review and meta- analysis. Medicina, 61 (2), 216.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Onyemekara, Darlington, Nwanjo Harrison Ugo, Nwadike Constance, Ejikunle Samson D, Ogoke Victor l, Mgbeojedo Chizoba, Ossai Joseph, Alagwu Grillo C, Ekenyem, Kieran C (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
